McGill University’s Clinical Innovation Competition supports the development of Prof. Uri Saragovi’s research on ovarian cancer tumor markers. AOA Dx to lead development and commercialization
AOA Dx Inc is excited to announce that they will be working with Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to lead the development and commercialization of a simple blood test for quantitative detection of ovarian cancer tumour markers. Therapy for ovarian cancer, the “silent killer”, is 80% effective, but the five-year survival rate is 9% due to late diagnosis and recurrent disease. Early diagnosis would offer greater opportunity for curative therapy.
RQRM Grant Awarded to technology licensed by AOA Dx. Prof. Uri Saragovi and Dr. Anne-Marie Mes-Masson were awarded a grant from the RQRM for initial tumor-ganglioside screening studies to enable early detection of cancers
AOA Dx Inc is proud to announce that Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, in collaboration with Dr. Anne-Marie Mes-Masson of the Centre hospitalier de l’Université de Montréal (CHUM) were awarded a grant from the Réseau Québécois de Recherche sur les Médicaments (RQRM). The work supported by the grant is the first of many steps demonstrating that gangliosides are an accurate and reliable marker to detect early stage cancers, and that tumor-gangliosides can be exploited for diagnostics in liquid biopsies. This award further demonstrates that world-leading scientists, such as Prof. Saragovi and Dr. Mes-Masson, are getting ever closer to accurate early-stage cancer diagnosis.
AOA Dx Files US Patent (No. 63,087427) for the identification of gangliosides as markers for ovarian cancer
AOA DX Inc is pleased to announce it has filed a US Patent (No. 63,087427) for the compositions and methods of ovarian cancer diagnosis. This is an important step in making a cost-effective, accurate and simple liquid-biopsy test for ovarian cancer diagnosis widely available. The application gives 20 years of patent protection for the methods, lasting until at least 2040. The filing protects the intervention of accurate detection of ovarian cancer.
AOA Dx signs exclusive option agreement to commercialize cancer diagnosis technology from Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University
AOA Dx Inc announces that it has signed an exclusive option agreement with Prof. Uri Saragovi providing exclusivity to develop and commercialize new cancer diagnostic technology. Ovarian cancer is the most lethal gynecologic cancer and the third cause of death in women. Tumors are classified based on cell type and further subdivided into benign, borderline and malignant (carcinomas), according to the aggressiveness. High Grade Serous Ovarian Cancer (HGSOC) is the most malignant and is labelled “the silent killer”. Symptoms are vague and easily confounded with other conditions. More than 70% of patients present to the clinic at advanced stages of disease, when surgical and therapeutic treatments become ineffective at extending life-span.